Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall

Liron Barnea Slonim; Shuo Ma; Amir Behdad; Qing Chen

doi:10.1111/bjh.16948

Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall

Liron Barnea Slonim^*, Shuo Ma, Amir Behdad, Qing Chen

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

15 Scopus citations

Original language	English (US)
Pages (from-to)	e22-e25
Journal	British Journal of Haematology
Volume	191
Issue number	1
DOIs	https://doi.org/10.1111/bjh.16948
State	Published - Oct 1 2020

Funding

SM received research funding from Abbvie, AstraZeneca, BeiGene, Genentech, Gilead, Janssen, Juno, Novartis, Pharmacyclics and TG Therapeutics; and received honorarium for advisory board or lecturing for Abbvie, AstraZeneca, BeiGene, Genentech, Gilead, Janssen, Kite and Pharmacyclics. AB received honorarium for lecturing for Bayer, Foundation Medicine and Pfizer. The other authors declare no conflicts of interest.

Keywords

chronic lymphocytic leukaemia
ibrutinib
lymphomas
non Hodgkin lymphoma

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.16948

Cite this

@article{77f55c49f366483eadc1427d56d9eca7,

title = "Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall",

keywords = "chronic lymphocytic leukaemia, ibrutinib, lymphomas, non Hodgkin lymphoma",

author = "{Barnea Slonim}, Liron and Shuo Ma and Amir Behdad and Qing Chen",

note = "Funding Information: SM received research funding from Abbvie, AstraZeneca, BeiGene, Genentech, Gilead, Janssen, Juno, Novartis, Pharmacyclics and TG Therapeutics; and received honorarium for advisory board or lecturing for Abbvie, AstraZeneca, BeiGene, Genentech, Gilead, Janssen, Kite and Pharmacyclics. AB received honorarium for lecturing for Bayer, Foundation Medicine and Pfizer. The other authors declare no conflicts of interest.",

year = "2020",

month = oct,

day = "1",

doi = "10.1111/bjh.16948",

language = "English (US)",

volume = "191",

pages = "e22--e25",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption

T2 - a diagnostic pitfall

AU - Barnea Slonim, Liron

AU - Ma, Shuo

AU - Behdad, Amir

AU - Chen, Qing

N1 - Funding Information: SM received research funding from Abbvie, AstraZeneca, BeiGene, Genentech, Gilead, Janssen, Juno, Novartis, Pharmacyclics and TG Therapeutics; and received honorarium for advisory board or lecturing for Abbvie, AstraZeneca, BeiGene, Genentech, Gilead, Janssen, Kite and Pharmacyclics. AB received honorarium for lecturing for Bayer, Foundation Medicine and Pfizer. The other authors declare no conflicts of interest.

PY - 2020/10/1

Y1 - 2020/10/1

KW - chronic lymphocytic leukaemia

KW - ibrutinib

KW - lymphomas

KW - non Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85088133379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088133379&partnerID=8YFLogxK

U2 - 10.1111/bjh.16948

DO - 10.1111/bjh.16948

M3 - Letter

C2 - 32677079

AN - SCOPUS:85088133379

SN - 0007-1048

VL - 191

SP - e22-e25

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this